Pfizer Sells 700 Million Haleon Shares, Pocketing $3.05 Billion!
In a strategic move, Pfizer has sold 700 million shares of Haleon, garnering $3.05 billion. This divestiture aligns with Pfizer's post-spinoff strategy and grants the pharma giant a substantial cash infusion for R&D and potential acquisitions. Meanwhile, Haleon's business remains steady, though its market valuation might see fluctuations from this block sale. Pfizer continues to streamline its operations post its consumer healthcare spinoff, paving the path for focused pharmaceutical advancements.
Jan 17